NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ: MDSO) announced that Memorial Sloan Kettering Cancer Center (MSK) is using Rave Omics with Biomarker Discovery for patients with pancreatic cancer, an example of the paradigm shift in clinical trials through the systematic capture of genomic data and the application of artificial intelligence algorithms. In doing so, MSK aims to obtain further actionable insights from the industry’s only unified eClinical platform, the Medidata Clinical Cloud®.
Memorial Sloan Kettering Cancer Center is at the forefront of precision medicine, pioneering the application of genomic biomarker insights to inform and improve patient treatment in oncology. MSK will now leverage Medidata Rave Omics in addition to Medidata Rave EDC for pancreatic cancer research to integrate clinical, genomic and proteomic data and leverage analytics in this pursuit.
Genomic data is increasingly being collected during clinical trials and is a critical enabler for more targeted therapies and groundbreaking discoveries. In fact, data from a third-party study1 highlighted clinical trials with molecular biomarkers have a higher success rate (25.9%) versus trials without biomarkers (8.4%). However, traditional workflows often lack a secure technology platform that can incorporate genomic data with other clinical data types to return insights around safety and efficacy in real time. Medidata Rave Omics with Biomarker Discovery provides a suite of solutions that seamlessly integrates clinical trial and genomic data, checks data quality and performs exploratory data analyses related to biomarker discovery using machine learning and advanced analytics - all within the Medidata Clinical Cloud.
“This project addresses MSK’s need to enhance the integration of large sets of genomic, transcriptomic, and proteomic data, with the extensive demographic, clinical and pathologic data we are collecting as part of our clinical research trials for pancreatic ductal adenocarcinoma,” said Dr. David Kelsen, Edward S. Gordon Chair in Medical Oncology, MSK. “The automated integration of large sets of genomic data from research laboratories will improve our ability to develop new diagnostic tests for early detection, and novel therapies, for patients with pancreatic cancer.”
Through the use of Rave Omics, MSK researchers are able to centralize the disparate sources of data commonly found in a cancer trial. By integrating the clinical, genomic and proteomic data of a trial in a single platform, researchers are able to quickly identify genomic-driven insights through comprehensive, automated statistical methods and machine learning. With the use of Rave Omics, MSK aims to streamline processes and expedite their research in pancreatic cancer.
“We’re excited to continue our long-term collaboration with MSK and help world-class researchers discover new pancreatic cancer treatments,” said Glen de Vries, president and co-founder, Medidata. “MSK’s use of Rave Omics will automate the integration of genomic data into clinical research and accelerate biomarker discovery."
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com
1 Clinical Development Success Rates 2006-2015: BIO, May 2016